Nob 2021: Ang unang klinikal na pagsubok ng homegrown next-generation chimeric antigen receptor T (CAR-T) cell therapy ng South Korea, na idinisenyo upang iwasan ang mga signal ng immune checkpoint, ay nagsimula kamakailan.
Inihayag ng Korea Advanced Institute of Science and Technology (KAIST) noong Miyerkules na ang isang Phase 1b na klinikal na pagsubok ng CAR-T cell therapy nito ay kasalukuyang isinasagawa sa Samsung Medical Center sa Seoul. Isinasagawa ang pagsubok sa 10 pasyenteng Koreano na nag-relapse at refractory diffuse large B cell lymphoma. Ang mga karapatan sa marketing para sa pipeline ay inilipat mula sa unibersidad patungo sa kumpanyang Curocell, na co-founded ni Propesor Kim Chan-hyuk. Si Curocell ang namamahala sa clinical development program ng rebolusyonaryo immunotherapy.
In addition, a Phase 2 klinikal na pagsubok involving seventy participants is going to take place the following year to assess how safe and effective the investigational medication is.
The acronym CAR T, which stands for receptor ng chimeric antigen T, is frequently referred to as a miracle cure. This is due to the fact that studies conducted in other countries on terminal blood cancer patients demonstrated that the therapy had a therapeutic effect of more than 80 percent. T cells from a patient are taken from the patient’s blood, genetically enhanced to make them more effective, and then reintroduced to the patient so that they can continue to fight and destroy cancer cells inside the patient’s body.
The research team that was led by Professor Kim of the Department of Biomedical Engineering at the KAIST confirmed an improved anticancer efficacy of CAR-T cells in mice with leukaemia and lymphoma. This was achieved by simultaneously inhibiting programmed cell death protein 1 (PD-1) and T-cell immunoglobulin and ITIM domain (TIGIT), both of which are known to disturb the function of T cells. According to Professor Lee Young-ho, a post-doctoral researcher at KAIST and the first author of the animal model study, this dual blockade of PD-1 and TIGIT is a novel strategy to overcome the immunosuppression of existing CAR-T cells. This strategy was discovered by Prof. Lee Young-ho.
Maaari mong basahin ang: CAR T-Cell therapy sa Korea
Ang mga natuklasan ng pag-aaral ay ipinakita sa isang artikulo na na-publish online sa Oktubre na isyu ng Molecular Therapy.
